Adco Retic 5mg/50mg Tablets

    Adco Retic 5mg/50mg Tablets

    S3
    PDF Leaflet Revision Date: 13 March 2023


    Clinical Summary

    Quick overview from the medicine insert

    Indication

    Treatment of oedema and essential hypertension.

    Dosage (summary)

    1-2 tablets daily for oedema; 1 tablet daily for hypertension.

    Special Populations

    • Paediatric population
    • Renal impairment
    • Hepatic impairment

    Pregnancy & Breastfeeding

    Contraindicated in pregnancy and lactation.

    Key Drug Interactions

    • Lithium
    • NSAIDs
    • ACE inhibitors

    Contraindications

    • Hypersensitivity
    • Severe hepatic failure
    • Hyperkalaemia
    • Impaired renal function

    Common side effects

    • Electrolyte imbalance
    • Dizziness
    • Nausea
    • Fatigue

    Counselling Points

    • Avoid potassium supplements
    • Monitor for skin lesions
    • Caution with driving if experiencing dizziness

    Serious warnings

    • Risk of nonmelanoma skin cancer
    • Potential for hyperkalaemia
    • Monitor renal function
    Important Disclaimer

    The Adco Retic 5mg/50mg Tablets professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

    Healthcare Professionals Only

    This content is for registered healthcare professionals

    Sign in or create a free account to read the full package insert.

    Free for HPCSA-registered professionals. Powered by Medinsert.

    Successfully Stashed! 💊

    This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

    View My Favourites
    WhatsApp Email LinkedIn